Karyopharm Therapeutics | KPTI - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.48B 110M 2026-03
Abbott USD 11.22B 655M 2026-03
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
BioCryst Pharmaceuticals USD 110.76M 3.94M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
GlaxoSmithKline GBP 8.07B 137M 2026-06
Incyte USD 1.13B 73.7M 2026-06
J&J USD 22.54B 1.21B 2026-03
Karyopharm Therapeutics USD 23.36M 2.82M 2026-03
MacroGenics USD 10.42M 2.95M 2026-03
Merck USD 12.21B 435M 2026-03
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Novartis USD 9.85B 252M 2026-06
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.19B 19M 2026-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sangamo BioSciences USD 581K 110K 2024-06
Takeda JPY 956.14B 79.79B 2026-06
Tectonic Therapeutic USD 0 270K 2023-12
TG Therapeutics USD 401.56M 9.52M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Xencor USD 42.23M 30.23M 2026-06